AU2002247939B2 - Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists - Google Patents
Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists Download PDFInfo
- Publication number
- AU2002247939B2 AU2002247939B2 AU2002247939A AU2002247939A AU2002247939B2 AU 2002247939 B2 AU2002247939 B2 AU 2002247939B2 AU 2002247939 A AU2002247939 A AU 2002247939A AU 2002247939 A AU2002247939 A AU 2002247939A AU 2002247939 B2 AU2002247939 B2 AU 2002247939B2
- Authority
- AU
- Australia
- Prior art keywords
- dao
- polypeptide
- seq
- ddo
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26188301P | 2001-01-16 | 2001-01-16 | |
| US60/261,883 | 2001-01-16 | ||
| US30544501P | 2001-07-13 | 2001-07-13 | |
| US60/305,445 | 2001-07-13 | ||
| US34521101P | 2001-10-22 | 2001-10-22 | |
| US60/345,211 | 2001-10-22 | ||
| US33388101P | 2001-11-19 | 2001-11-19 | |
| US60/333,881 | 2001-11-19 | ||
| PCT/IB2002/001262 WO2002066672A2 (en) | 2001-01-16 | 2002-01-15 | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2002247939B9 AU2002247939B9 (en) | 2002-09-04 |
| AU2002247939A1 AU2002247939A1 (en) | 2003-02-27 |
| AU2002247939B2 true AU2002247939B2 (en) | 2007-01-25 |
Family
ID=27500728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002247939A Ceased AU2002247939B2 (en) | 2001-01-16 | 2002-01-15 | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1412515A2 (es) |
| JP (1) | JP2004537275A (es) |
| KR (1) | KR20030066813A (es) |
| CN (1) | CN1568370A (es) |
| AU (1) | AU2002247939B2 (es) |
| BR (1) | BR0206495A (es) |
| CA (1) | CA2433866A1 (es) |
| EA (1) | EA006654B1 (es) |
| IL (1) | IL156865A0 (es) |
| MX (1) | MXPA03006321A (es) |
| WO (1) | WO2002066672A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2446136C (en) | 2001-05-03 | 2011-07-05 | Galileo Pharmaceuticals, Inc. | Pyruvate derivatives |
| WO2003070743A1 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF G72 AND D-AMINO ACID OXIDASE (DAAO) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1291015A1 (en) | 2001-09-10 | 2003-03-12 | Lunamed AG | Dosage forms having prolonged active ingredient release |
| US20030162825A1 (en) * | 2001-11-09 | 2003-08-28 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
| WO2003047558A2 (en) * | 2001-12-03 | 2003-06-12 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| IL162481A0 (en) * | 2001-12-12 | 2005-11-20 | Genset Sa | Method and use of determining genotype |
| GB0223424D0 (en) * | 2002-10-09 | 2002-11-13 | Imp College Innovations Ltd | Disease-associated gene |
| JP2007517056A (ja) | 2003-12-29 | 2007-06-28 | セプラコア インコーポレーテッド | ピロール及びピラゾールｄａａｏ阻害剤 |
| JP5367377B2 (ja) * | 2006-01-09 | 2013-12-11 | オクラホマ メディカル リサーチ ファウンデーション | 炎症性疾患治療のためのランチオニン関連化合物 |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| GB2456390A (en) * | 2008-01-15 | 2009-07-22 | Glaxo Group Ltd | Bipolar disorder treatments |
| EP3006023B1 (en) | 2009-01-20 | 2019-06-26 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Sorbic acid and derivatives thereof to enhance the activity of a neuropharmaceutical |
| JP4462382B1 (ja) * | 2009-04-23 | 2010-05-12 | 学校法人北里研究所 | Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤 |
| WO2012135119A1 (en) * | 2011-03-25 | 2012-10-04 | Genomind, Llc | Biomarker-based detection and treatment of neurodegenerative depression |
| CA2866392C (en) | 2012-03-30 | 2023-10-24 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| KR102338171B1 (ko) | 2016-06-13 | 2021-12-09 | 신유알엑스 인터내셔널 (타이완) 코포레이션 | 벤조산리튬의 공-결정 및 그의 용도 |
| ES2936094T3 (es) | 2016-06-13 | 2023-03-14 | Syneurx Int Taiwan Corp | Cocristales de benzoato de sodio y usos de los mismos |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10336679B2 (en) | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| CN108504752B (zh) * | 2018-06-26 | 2021-05-11 | 华中农业大学 | 一种与母猪繁殖性状关联的分子标记及应用 |
| CN111909907B (zh) * | 2020-07-08 | 2022-05-24 | 浙江工业大学 | 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| AU778868B2 (en) * | 1999-03-30 | 2004-12-23 | Serono Genetics Institute S.A. | Schizophrenia associated genes, proteins and biallelic markers |
| WO2001009118A2 (en) * | 1999-07-29 | 2001-02-08 | Patrick T Prendergast | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement |
| AU2001247474A1 (en) * | 2000-03-16 | 2001-09-24 | The Mclean Hospital Corporation | Compounds for the treatment of psychiatric or substance abuse disorders |
-
2002
- 2002-01-15 WO PCT/IB2002/001262 patent/WO2002066672A2/en active Application Filing
- 2002-01-15 CN CNA028066650A patent/CN1568370A/zh active Pending
- 2002-01-15 EP EP02717019A patent/EP1412515A2/en not_active Withdrawn
- 2002-01-15 EA EA200300807A patent/EA006654B1/ru not_active IP Right Cessation
- 2002-01-15 MX MXPA03006321A patent/MXPA03006321A/es unknown
- 2002-01-15 AU AU2002247939A patent/AU2002247939B2/en not_active Ceased
- 2002-01-15 BR BR0206495-2A patent/BR0206495A/pt not_active IP Right Cessation
- 2002-01-15 IL IL15686502A patent/IL156865A0/xx unknown
- 2002-01-15 CA CA002433866A patent/CA2433866A1/en not_active Abandoned
- 2002-01-15 KR KR10-2003-7009412A patent/KR20030066813A/ko not_active Application Discontinuation
- 2002-01-15 JP JP2002566376A patent/JP2004537275A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002066672A3 (en) | 2004-02-26 |
| CA2433866A1 (en) | 2002-08-29 |
| IL156865A0 (en) | 2004-02-08 |
| EP1412515A2 (en) | 2004-04-28 |
| EA006654B1 (ru) | 2006-02-24 |
| EA200300807A1 (ru) | 2004-08-26 |
| BR0206495A (pt) | 2006-01-24 |
| JP2004537275A (ja) | 2004-12-16 |
| KR20030066813A (ko) | 2003-08-09 |
| CN1568370A (zh) | 2005-01-19 |
| AU2002247939B9 (en) | 2002-09-04 |
| MXPA03006321A (es) | 2003-10-06 |
| WO2002066672A2 (en) | 2002-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002247939B9 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
| AU2002247939A1 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
| WO2003047558A2 (en) | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors | |
| Wang et al. | Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions | |
| JP4018884B2 (ja) | 脊柱筋萎縮症の治療 | |
| Gutiérrez et al. | Nitric oxide interacts with monoamine oxidase to modulate aggression and anxiety-like behaviour | |
| CA2257857A1 (en) | Screening methods for compounds useful in the regulation of body weight | |
| MX2007015225A (es) | Chaperonas farmacologicas para el tratamiento de obesidad. | |
| US20070099830A1 (en) | Sirt4 activities | |
| Mast et al. | In vitro activation of cytochrome P450 46A1 (CYP46A1) by efavirenz-related compounds | |
| WO2014179303A1 (en) | Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease | |
| US20030185754A1 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
| Loureiro et al. | N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor | |
| Willemse et al. | UNC13A in amyotrophic lateral sclerosis: from genetic association to therapeutic target | |
| US6248528B1 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
| Tarazi et al. | Brain dopamine D4 receptors: basic and clinical status | |
| JP2011501672A (ja) | 腸疾患における新規な治療上の標的 | |
| Ciaranello et al. | Genetic regulation of neurotransmitter enzymes and receptors: Relationship to the inheritance of psychiatric disorders | |
| US20030166554A1 (en) | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists | |
| JP2005525112A (ja) | ジアシルグリセロールキナーゼεを使用して疼痛を処置する際の方法および組成物 | |
| EP0915706A1 (en) | Screening methods for compounds useful in the regulation of body weight | |
| Morse et al. | Pharmacogenetics of cocaine: a critical review | |
| WO1999051762A9 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
| JP2005518346A (ja) | ドパミン作動性ニューロンの調節 | |
| Murray | Amyotrophic lateral sclerosis: new research |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT/PATENTEE FROM GENSET TO GENSET S.A. |
|
| TC | Change of applicant's name (sec. 104) |
Owner name: SERONO GENETICS INSTITUTE S.A. Free format text: FORMER NAME: GENSET S.A. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| SREP | Specification republished | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |